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Recent medical advances in the field of regenerative medicine and tissue transplantation have highlighted the importance of umbilical 
cord blood (UCB) as a valuable alternative source of haematopoietic stem cells, which are potentially life-saving in a vast array of clinical 
applications. Although less controversial than the use of embryonic stem cells obtained from fetal tissue, the practice of UCB biobanking 
presents several ethical and regulatory challenges surrounding its procurement and use, especially in developing countries like South 
Africa, where the  majority of the population is vulnerable and prone to exploitation. Currently only private umbilical cord banking is prac-
tised in South Africa and the regulatory framework for human tissue use is still rudimentary with no clear guidelines. This environment 
raises ethical questions about consent and ownership of tissues, the cost-effectiveness of harvesting and storage of UCB, undue influ-
ence on donors, and issues of distributive justice such as the fact that UCB, which is potentially life-saving and could be easily obtained, 
may become a resource unfairly restricted only to the wealthy. In view of the fact that UCB has become a valuable, non-invasive source 
of stem cells for regenerative therapy, establishment of a public cord blood bank (CBB) in South Africa would vastly improve the avail-
ability of haematopoietic stem cells for research and therapeutic uses, and increase the tissue genetic diversity that currently impedes 
the South African bone marrow registry.
What is umbilical cord blood 
banking and why is it important?
In the novel and exciting field of regenerative medicine, 
umbilical cord blood (UCB),  also known as placental blood, is 
no longer considered biological waste.1,2 UCB is the blood in 
the cut umbilical cord and placenta after delivery. Derived from 
the fetal allantois, it provides a rich source of multipotent stem 
cells, including CD34+ and CD38- haematopoietic progenitor 
cells. These progenitor cells have greater clonal expansion and 
proliferative capacity than normal bone marrow cells. As a source 
of non-embryonic stem cells, UCB has found potential uses as 
a therapeutic modality in more than 80 clinical applications, both 
haematological and non-haematological.2 UCB is at the forefront 
of research exploring gene therapy, prenatal diagnosis, immune 
cell therapy, antibiotic efficacy and identification of new proteins.2,3 
Normally, the bone marrow serves as the source for replenishing 
the cellular components of peripheral blood including red and 
white blood cells and platelets. Deficiency or malfunction of 
these blood cells occurs in disease conditions prevalent in Africa, 
including cancers like leukaemia and haemoglobinopathies like 
thalassaemia or sickle-cell disease. UCB may also be used to 
reconstitute the bone marrow after high-dose chemotherapy or 
radiotherapy. UCB’s advantages over other sources of stem cells 
such as adult bone marrow and embryonic stem cells include easy 
procurement, minimal risk to the donor, excellent proliferation and 
differentiation, immediate availability, and autologous use. UCB 
also has greater tolerance of HLA disparity with lower risk of graft-
versus-host disease (GVD).4 Limitations of UCB include once-off 
collection/donation, sometimes yielding small volumes less than 
40 ml, containing <120 million nucleated cells. This may lead to 
inadequate engraftment in some adult patients.5 Homing and stem 
cell expansion are being researched to overcome these obstacles 
militating against wider use of UCB.6
In 1983 Koike7 showed that UCB-derived stem cells could be 
frozen and stored for future use. Following the first successful 
transplant/treatment of a child with Fanconi’s anaemia using his 
sibling’s cryopreserved UCB,8 many successful UCB transplants 
followed, leading to establishment of the first public cord blood 
bank (CBB) at the New York Blood Centre.4,9 Subsequently, many 
public and private CBBs have been established globally.3-5 In 1996, 
funding was awarded by the National Institutes of Health (NIH) for 
UCB banks to conduct national safety and efficacy trials.9 With im-
proved standardisation techniques, over 600 000 units of UCB are 
reportedly banked worldwide, while over 14 000 UCB transplants 
have been performed successfully.2 The two South African case 
scenarios reported in Table I illustrate some ethical challenges 
arising during treatment of patients with life-threatening illnesses 
in developing countries, and the potential advantages of UCB 
biobanking.
Private versus public CBBs
UCB is collected and stored by two primary mechanisms:
Public (not-for-profit) CBBs are publicly owned and usually 
funded by governments. They collect UCB from any willing do-
nor, which are then stored and used for transplantation to benefit 
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any suitable public recipient for whom the blood/stem cells are 
a match. The majority of recipients benefiting are unrelated allo-
geneic transplant patients. UCB collected by this mechanism can 
also be used for laboratory-based research benefiting society in 
general. 
Private (for profit) CBBs usually collect UCB on behalf of expect-
ant parents for potential use by a child for autologous transplanta-
tion or a family member in need of stem cell transplant through 
directed allogeneic transplantation.
Table II outlines the operational differences between private and 
public CBBs. 
Ethical dilemmas arising from UCB 
biobanking
Beneficence and non-maleficence 
One ethical basis for UCB use is the physician’s obligation to pro-
vide benefit to the patient while minimising risk/harm caused by 
other disease conditions.3 The use of UCB-derived stem cells in 
research has the potential to help conquer a broad spectrum of 
previously incurable conditions, thereby alleviating human suffer-
ing. However, the physician’s obligation of non-maleficence (do 
no harm) may be contravened if effective quality control (QC) is 
not rigorously maintained. This may occur in private CBBs where 
a conflict may arise between the need to maximise profits and 
maintaining the expected ‘standard of care’ in QC, including as-
sessment of cellular viability, sample volume, methods of acquisi-
tion and transportation, leading to poor overall quality of collected 
UCB units.3 These dangers are magnified in developing countries 
like South Africa where the regulatory framework is not clear and 
applicable laws are not rigorously enforced.10 It has been observed 
that while public CBBs are regulated by stringent international QC 
standards, private CBBs use less stringent QC methods when col-
lecting and storing UCB. These violations of established standards 
include use of untrained personnel to collect UCB at the time of 
birth and storage of inadequate volumes, leading to a situation 
where clients of private CBBs may finance storage of samples 
later found insufficient for the purpose envisaged.5,9 The use of 
UCB for autologous transplant in malignant diseases or inheritable 
genetic disorders has also been criticised because the cancerous 
potential of the UCB cannot be completely excluded because of 
genetic factors in donors.11A lack of clinical and genetic informa-
tion about unrelated donors at public CBBs may also result in the 
transfer of abnormal cells even where careful screening has been 
implemented.9 In the above circumstances the ethical obligations 
for beneficial use of a valuable healthcare resource may come 
into conflict with the ethical obligation to  avoid harm, creating di-
lemmas that need to be carefully considered before choosing an 
appropriate regulatory framework for collection, storage and use 
of UCB.
Respect for autonomy, informed consent and 
ownership
Ownership of UCB is sometimes debatable since the umbilical 
cord is embryologically derived from the fetal allantois; it may be 
considered property of the child. However, UCB is usually col-
lected with the consent of the mother.5 One alternative view is 
that UCB is the property of the mother once the cord is cut, and a 
‘gift’ to the child.12 In many private banks, ownership transfers to 
the child once he/she comes of age. However in English as well 
as South African law, legal personhood begins at birth. ‘A fetus 
which is born and lives ex utero, even if only briefly, becomes 
a legal person and acquires all the rights and status thereto at-
tached.’13,14 However, although a newborn baby is recognised as 
a legal person by law, he/she does not have the capacity to pro-
vide informed consent. Storage of his/her UCB for several years 
could be arguably considered a manipulation of human tissue 
without the owners’ consent.12,15 Future conflicts could foresee-
Table I. Case scenarios illustrating potential benefits of UCB banking in South Africa
Case scenario A
Patient A was first diagnosed with acute lymphoblastic leukaemia (ALL) at age 2. He was treated as a medium-risk patient accord-
ing to stratification criteria. He achieved remission on completion of maintenance chemotherapy within 4 years of diagnosis and was 
closely monitored by the haematology/oncology team.  Less than a year later, he presented with testicular relapse. At this stage he is 
in remission but remains at ‘high risk’ for future relapse. If this occurs, the ideal treatment would be:
1. A human leucocyte antigen (HLA)-matched identical sibling bone marrow transplant (unavailable)
2. An HLA-matched sibling transplant (unavailable)
3. An unrelated bone marrow transplant (preliminary search of local bone marrow registry revealed no matched potential donors; an 
international registry search is cost-prohibitive and too expensive for his family).
His mother is not in favour of the only available option for him, which is palliative chemotherapy, indicating terminal illness. She has 
recently raised the possibility of having another baby that could serve as a ‘saviour sibling’ for him, by providing life-saving stem cells 
from umbilical cord blood. She is exploring the concept of having this baby naturally or genetically selected as a ‘designer baby’ guar-
anteed to be a matching-tissue donor for the son diagnosed with ALL.
Case scenario B
Patient B is a 3-year-old girl with severe aplastic anaemia, a clinical condition where the bone marrow cannot produce peripheral 
blood cells. The child presents with recurrent life-threatening bleeding secondary to thrombocytopenia – very low platelet counts in 
the blood, which is unresponsive to medical treatment. She has no HLA-compatible siblings following testing, and her parents are 
currently raising funds for a local bone marrow registry search. However, because of her ethnic origin and the lack of genetic diversity 
within the potential donor pool, the likelihood of finding a matching donor is very slim.
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ably arise where such tissues are needed for use by an ailing 
sibling, as demonstrated in the case of McFall v Shimp where an 
individual who was identified as a compatible bone marrow donor 
to his cousin diagnosed with aplastic anaemia, refused to serve 
as a transplant donor for the treatment of his dying cousin. The 
court found it would be unjustifiable to compel any individual to 
serve as a donor  contrary to the principle of self-determination 
and freedom of choice.16 Similarly in Re Y, the court ruled that 
a mentally disabled sibling could not serve as a bone marrow 
donor for her sister who was diagnosed with a pre-leukaemic 
disorder, except if it was in her ‘best interests’ to do so.17Another 
potential area of conflict lies within the provisions of the current 
National Health Act of 2003 which allows a donor to withdraw do-
nated tissue at any time before its use.15 In other words, the par-
ent/mother could provide consent for storage of UCB in anticipa-
tion of future use by another family member. However, the adult 
child would then be required to authorise use of such tissue in the 
future, where any adult patient has the legal right of refusal even 
when the stored tissue is to be used for the benefit of a sibling. 
This scenario presents some potential ethical and legal conflicts 
which have to be carefully regulated through specific guidelines, 
that might best be obviated through upfront regulations laid down 
a priori by any ‘authority’ charged with regulation of public and 
private CBBs. It could be argued that ideally such a regulatory 
framework should be outlined within the proposed ‘regulations 
relating to tissue banks’ with reference to section 8 of the Na-
tional Health Act of 2003, as recently published for comments by 
the Minister of Health in the Government Gazette of April 2011.18
Information disclosure and understanding
Generally proponents of private CBBs argue that the quality of 
graft is superior with autologous use which assures about 100% 
compatibility; therefore use of stored UCB would extend to other 
family members. Most transplants from privately stored UCB are 
reportedly performed on siblings of the donor.11 Private CBBs ad-
vertise that availability and use of stored UCB will be immediate, 
but in developing countries like South Africa, where UCB is some-
times stored overseas because of absent local infrastructure, 
there could be delays in availability. Currently there are about 
three private CBBs in South Africa, of which one or two store 
UCB locally while the rest store collected UCB abroad. It is not 
clear whether this information is clearly communicated or under-
stood by clients/parents. Further, the procedure for external stor-
age in these cases could also be considered exportation of tis-
sue with subsequent importation which could run contrary to the 
provisions of the National Health Act .15 While most international 
ethical committees discourage the activities of private CBBs by 
requiring strict regulation and close supervision, freedom of en-
terprise and choice of individuals and parental rights must also 
be respected. Parental consent on behalf of children needs to be 
adequately informed and obtained by qualified persons well in 
advance of the emotional birth process, to allow adequate time 
for reflection and minimise undue pressure. Comprehensive in-
formation booklets provided to prospective donor parents should 
be made available at antenatal visits to facilitate full information 
disclosure. Preferably this booklet should be translated into lo-
cal languages to facilitate comprehension. It has been suggested 
that the validity of consent obtained by private banks may be 
Table II. Main operational differences between private and public banks 
Public banks Private banks
Financing systems State funded Collection, testing, transport and storage costs all 
paid by donor (parents)
Access Available to any suitably matched recipient in need Only to those who can afford service. Majority of 
units collected remain unused (wasted)
Acquisition of samples By trained personnel at selected designated hos-
pitals – donors restricted to delivery at designated 
sites
By third party (potentially untrained); also possibility 
of financial incentive for personnel engaged in UCB 
collections
Quality assurance Better adherence to quality standards, cellular vi-
ability control 
Not always affiliated to international groups certify-
ing adherence to quality standards
Only samples that meet specified criteria in terms of 
volume/quality are stored
All samples are stored irrespective of volume/total 
nucleated dose
Availability Not immediate, depends on HLA bioarchive Immediate – where the CBB is located locally in the 
same country
Potential delays – where the CBB is stored in a dif-
ferent country overseas because of absent local in-
frastructure, e.g. South Africa
Compatibility Ranges up to 90% with HLA bioarchive 100% assured – when used by other family mem-
bers
Consent Often obtained at time of delivery – not optimal Obtained well before birth – adequate reflection
Potential for coercion , undue influence or manipula-
tion – advertised as ‘biological insurance’
May make unsubstantiated claims of use in condi-
tions that are in fact speculative
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questionable because of emotional coercion, as the service is of-
ten touted as ‘biological insurance’.5 Information given to parents 
must include details of the collection procedure, costs, storage 
methods and potential uses of UCB, including possible use for 
research. Prospective donor/parents should also be informed of 
their inability to direct the use of UCB stored in a public CBBs.3, 
5 When blood is collected by public CBBs consent is often ob-
tained around the time of delivery which may be unethical, since 
the emotional process at birth could unduly influence the moth-
er’s ability to provide valid consent.5 
Distributive justice and human rights
Storage of UCB for autologous use in private CBBs is viewed 
by several international ethical authorities as a wasteful practice 
of self-preservation19-23 which may promote social discrimination 
based on wealth. The odds of needing a non-autologous UCB 
transplant range from 1:1 000 to 1:20 000. The likelihood of finding 
a suitable HLA- matched donor in a public CBB is higher, since 
there is a greater tolerance for HLA disparity with UCB. On the 
other hand, the likelihood of requiring autologous UCB transplant 
is extremely low (as little as 0.0005%).4,5 Private banks are gener-
ally seen as competing with public banks for a valuable biologi-
cal resource which contradicts the principles of altruism in human 
tissue donation.3 Society has an obligation to protect the vulner-
able and ensure equal access to healthcare. Voluntary donation 
of UCB to public banks resembles regular blood donation which is 
altruistic and promotes social justice. Private banking for autolo-
gous/family use creates problems of inequitable access to health-
care services. The European Group on Ethics (EGE) advises that 
the donation of human tissues must be free and altruistic. Donors 
should not receive remuneration; this would avoid exploitation of 
the disadvantaged in society.3,24,25 This reaffirms the principles of 
non-commercialisation of human tissues, and respects human 
dignity.
Privacy and confidentiality
Consent and privacy are important issues for all DNA biobanks, 
not just CBBs.26 Privacy is of special concern in collecting, testing, 
and storing UCB because the source of blood is a newborn. While 
there are no physical risks in collecting UCB, there are significant 
risks to privacy. It is generally agreed that it is unethical to test 
children for genetic disorders for which there are no current pre-
ventive measures or therapy. It is possible that some additional 
useful information about safety of UCB could be gained by follow-
ing such children as they grow older. However, surveillance seems 
impractical and may constitute an invasion of privacy.26 Further, 
when UCB is used for research or therapy, it must be screened 
for a variety of diseases, including HIV/AIDS and other genetic 
disorders. Some private banks do not store HIV-infected blood. 
This may be construed as a form of discrimination, especially in 
countries like South Africa where the burden of HIV/AIDS is very 
high. HIV-infected patients are also predisposed to malignant dis-
ease and blood dyscrasias, and may arguably benefit more from 
UCB transplantation. Records of UCB donors and recipients must 
be kept confidential and afforded the full protection of the law.23 
If a genetic abnormality or infection is discovered during testing, 
the results must be delivered to the donor/parent/guardian in a 
manner that is appropriate in relation to the severity of the abnor-
mality with appropriate counselling. Consideration should be given 
to an ‘opt-in/opt-out’ choice for disclosure of abnormal results to 
respect patient autonomy and freedom of choice.9 Again, informa-
tion regarding the available choices should be included as part of 
the comprehensive information booklet and should become part 
of the informed consent process. It could be argued that in private 
CBBs, this notification and requirements for information disclosure 
may not meet rigorous ethical standards for disclosure because 
the objective of such entities is commercial success. Therefore 
such standards of information disclosure must be clearly legislated 
and enforced. 
Other potential ethical conflicts regarding privacy and confiden-
tiality have been highlighted. For example, during a study by 
Rubenstein and others,4 tests for haemoglobinopathies and other 
genetic diseases were performed on the basis of family history 
and ethnic background. Where UCB is linked to the donor, screen-
ing creates a medical information pathway about the child which 
has the potential to expose the mother’s ‘private history’ as well.26 
This leaves two options: either the mother’s fully informed consent 
needs to be obtained to perform the screening tests and steps 
taken to inform her of the test results while keeping them confi-
dential from others, or the UCB must be anonymised so that it 
cannot be linked to its source. Finally, it has been suggested that 
the best policy for the storage of non-autologous UCB, from the 
standpoint of privacy, would be complete de-identification of sam-
ples, so they could be freely tested without simultaneous testing of 
the mother and child.26 The issue of privacy and confidentiality of 
UCB biobanking contains potential pitfalls that could lead to many 
ethical and legal dilemmas. These need to be further regulated 
by specific guidelines separate from those available from general 
confidentiality laws.
Ethical and regulatory perspectives 
from international bioethics 
committees
The practice of UCB banking has come under scrutiny for ethical 
conflicts by some international bioethics committees, including 
those from the European Union.19-25 Opinions of different com-
mittees appear unanimous in their evaluations of controversies 
surrounding private and public banking. In 2004, the European 
Group on Ethics in Science and New Technologies (EGE) ad-
vised the European Commission that ‘the legitimacy of commer-
cial CBBs for autologous use should be questioned’ and warned 
that advertising must be adequately controlled by public authori-
ties. They also recommended that support for public CBBs for 
allogeneic transplantations should be increased.25 The Royal 
College of Obstetrics and Gynaecology (RCOG) advised that 
the collection of non-directed and directed donations for ‘at-risk 
families’ are acceptable through public CBBs, but there is insuffi-
cient evidence to recommend collection and storage for ‘low-risk 
families’. Emphasis was placed on the fact that patients must 
be fully informed of their rights and financial obligations in the 
case of private banking, and research should continue on UCB 
use for stem cell therapy.22 By 2004, the European Union (EU) 
issued directives on tissues and cells aiming to establish a har-
monised approach to regulation across Europe. The directives 
set benchmarks for standards that must be met when carrying 
out any activity involving tissues and cells for human application 
or patient treatment. The regulations also require that systems 
be put in place to ensure that all tissues and cells used in human 
application are traceable from donor to recipient.27 These direc-
tives were adopted into UK domestic law in 2007. They make 
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provisions for procurement, testing, processing, storage and dis-
tribution, including import and export of human tissues.28 Many 
reports indicate that private CBBs usually collect UCB for parents 
as an ‘insurance policy’ against future catastrophes. The Ameri-
can College of Obstetrics and Gynecology (ACOG) opined that: 
‘Parents should not be sold this service without a realistic look at 
the “return” of their investment and that commercial cord blood 
banks should not market their highly speculative market services 
as “doing everything possible”.’19 
Similarly, the American Academy of Pediatrics (AAP) concluded 
that philanthropic donation of cord blood for banking at no cost 
for allogeneic transplantation should be encouraged20 while a re-
cent policy update21 stated: ‘Cord blood donation should be dis-
couraged when cord blood stored in a bank is to be directed for 
later personal or family use, because most conditions that might 
be helped by cord blood stem cells already exist in the infant’s 
cord blood … Given the difficulty of making an accurate estimate 
of the need for autologous transplantation and the ready avail-
ability of allogeneic transplantation, private storage of cord blood 
as “biologic insurance” is unwise.’ 
Some important issues that may 
require specific regulation
Advertising. Advertising must be clear about the potential ben-
efits for clients of private CBBs and should indicate explicitly 
the negligible odds that the sample will be needed for autolo-
gous use, and that some future therapeutic possibilities might 
be found to be remote. Advertising needs to be controlled by 
local authorities.22
Commercialisation and patenting. Further clarification needs 
to be made regarding the commercial gains from UCB research 
from donated units.24,29
Relationships between patients, doctors and CBBs. Finan-
cial incentives for medical personnel collecting UCB for private 
CBBs have been implemented by some private banks (anecdo-
tal evidence) however the American Medical Association (AMA) 
advises that: ‘Physician’s ties to public and private cord blood 
banks must be disclosed during the informed consent process 
and physicians should not accept financial or other induce-
ments for providing samples to CBBs.’12 Information must be 
provided to private clients regarding the storage and safety of 
their ‘investment’ in the event of termination of business either 
by bankruptcy or natural disasters. Perhaps new regulations 
should include provisions for insurance and compensation in 
case of loss or damages.
‘Designer babies’ and ‘saviour siblings’. The issue of de-
signer babies and saviour siblings creates moral conflicts that 
require careful ethical consideration. Concerned parents may 
request that physicians create a test-tube baby with the pre-
implantation characteristics necessary to serve as a ‘saviour 
sibling’ for an ailing child. Should routine acceptance of these 
requests become the norm, it may lead down a slippery slope 
and open floodgates with implications for eugenics. Further, it 
has the potential to result in severe emotional distress and pos-
sible stigmatisation for both the donor and recipient siblings in 
future life. 
The case for establishment and 
regulation of public/private CBBs in 
South Africa
Stem cell use in South Africa is currently governed by the Human 
Tissue Act (Act 65 of 1983)30 which states that written consent from 
the donor(s) be given for the removal/withdrawal of tissue unless 
such tissue is replaceable by natural processes, in which case 
consent may be oral.29 Further, placental, fetal tissue and umbilical 
cord tissue may only be withdrawn with the consent of the Min-
ister subject to any conditions mentioned in the consent.24 Since 
healthcare priorities in most developing countries remain preven-
tive medicine and the provision of basic healthcare services, UCB 
banks have been predominantly established in developed coun-
tries with the exceptions of Mexico, China and Argentina.3,31 In view 
of the costs involved in establishing and maintaining a CBB that 
would mirror the genetic diversity of the local population, relative 
to the benefits and actual potential for use, the establishment of 
public CBBs in South Africa has so far not been feasible. For those 
who can afford them, private CBBs are the only option for storage 
of UCB, and this further increases inequitable access to healthcare 
services in South Africa. While the Bill of Rights guarantees a right 
of access to healthcare services, the problem is that despite the 
potential benefits of UCB biobanking, the government cannot fund 
all healthcare services where there are many competing needs 
such as the large burden of HIV/AIDs, tuberculosis and other dis-
orders as demonstrated by the Soobramoney case.32 However, 
there may be room for public-private partnership (PPP) in such 
a way that the government provides the appropriate regulatory 
framework and guidelines, while non-governmental organisations 
(NGOs) endeavour to establish and run public CBBs within speci-
fied rules with the resulting goal of enormous public good. This is 
especially of relevance in terms of the future plans for implemen-
tation of the proposed National Health Insurance (NHI) scheme in 
South Africa. The government could also explore other creative 
mechanisms for funding such as imposing levies or a tax on all 
private UCB collections stored in South Africa, with a percentage 
of the revenue generated used for establishment of a public CBB 
run on a (PPP) fee-for-service basis. These regulations could be 
incorporated into the new guidelines envisaged when section 8 of 
the National Health Act, dealing with human tissues, comes into ef-
fect in the near future.18 Further, establishment of  public CBBs or 
preferably a central national CBB with satellite branches within dif-
ferent provinces in South Africa would vastly improve  availability 
of genetically diverse tissues for transplant, and help to resolve the 
problem of genetic diversity that currently impedes the South Afri-
can Bone Marrow Registry.33Another consideration in the context 
of establishing a public CBB in South Africa is the high prevalence 
of HIV and hepatitis B.34 The protocols for screening donated UCB 
for transmissible infections will need to be stringent and may be 
costly, thereby requiring creative funding and specific regulation. 
It has been argued that since stem cell research is financially lucra-
tive for private enterprises, the potential uses of UCB in research 
and therapy may present another opportunity for exploitation of 
vulnerable Africans. In the absence of an appropriate regulatory 
framework, commodified human tissues including stem cells from 
UCB may be surreptitiously exported elsewhere for commercial 
research purposes.29 Private CBBs could potentially capitalise on 
this regulatory vacuum to exploit local donors/clients without their 
knowledge.24
84         December 2011, Vol. 4, No. 2  SAJBL
    Article
Conclusion
UCB biobanking as a measure to achieve the common good is 
an example of a social justice health model. As with any other sci-
entific advances, it is necessary to closely analyse the impact on 
social, ethical, moral and legal frameworks before implementing 
such public policies. In South Africa, the concept of UCB biobank-
ing must be explored in order to keep pace with the needs of a 
changing population, and to contribute and benefit from interna-
tional collaborations in tissue transplantation. For these reasons 
a specific regulatory framework providing guidance on UCB stor-
age and use needs to be developed. This must provide specific 
guidelines for ownership, informed consent, procurement, testing, 
storage and distribution including import/export and the financial 
implications for donors and recipients. Part of the problem for the 
current state of affairs is due to the vacuum created by the non-im-
plementation of section 8 of the National Health Act of 2003. While 
new regulations may trigger some negative reaction especially 
from commercialised private CBBs, who may perceive a central-
ised public CBB as competition, the potential for enormous public 
good would override these concerns. Further, establishment of a 
centralised public CBB through a PPP mechanism will help the 
new NHI scheme towards achieving its goal of equity of access 
and availability of healthcare services to the majority of South Af-
rican citizens. This will be achieved through appropriate regula-
tions. Any conflicts triggered by the new regulations could be dealt 
with at central level through an inclusive process of discussion 
between the public and private stakeholders. A previous reviewer 
of this paper has suggested that investigating the conversion and 
absorption of the current Bone Marrow Registry into a centralised 
public CBB would be beneficial if achievable; however achieving 
this laudable objective may require the appointment of either a 
Presidential or Ministerial Advisory body, preferably a Presidential 
Advisory Board with the Minister of Health chairing it in order to 
deal with the socio-political implications involved.
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